Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer
Status:
Active, not recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
High-risk locally advanced carcinoma of the cervix (HRLACC) following concurrent chemotherapy
and radiation therapy. This is a group of patients with a significant unmet need. The
estimated probability of disease recurrence or death within 4 years of diagnosis is 50% and
the prognosis is very grave for those who experience a recurrence.
The purpose of the study is to compare the disease free survival (DFS) of ADXS11-001 to
placebo administered following CCRT with curative intent in subjects with HRLACC.